drugset
drugset / Trial / NCT03364985

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

NCT03364985 ↗

Phase 1 Completed 123 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a dose block-randomized, double-blind, placebo- and active-controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of DWP16001 after oral administration in healthy male volunteers.

Timeline

Start
2017-12-03
Primary completion
2019-05-21
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule — Oral
Subject Enavogliflozin Small molecule — Oral

Indications

No indication recorded.